Chair(s)
Dr Vivien Tong, ExCo member FIP Health and Medicines Information Section, Australia and Dr Timothy Chen, ExCo member FIP Social and Administrative Pharmacy Section, AustraliaIntroduction
During this session selected abstracts from the following topics will be presented in a 7,5-minute presentation:
- Health and medicines information
- Social and admin. pharmacy
Link to selected abstracts to follow
(SEC) Health and medicines information- RFMO-02-01 - Consumer and clinician perspectives on adverse drug events and adverse drug withdrawal effects of heart failure medications in frail older people
- RFMO-02-02 - Characteristics, content and language of deprescribing recommendations in clinical practice guidelines: A scoping review
- RFMO-02-03 - Not just being old or forgetful - measuring and quantifying causes of medication non-adherence in Norway
- RFMO-02-04 - Tech-ing up pharmacy: creating a framework to evaluate health information communication technology
- RFMO-02-05 - An exploration of drivers of COVID-19 vaccine hesitancy in Kenya
- RFMO-02-06 - Exploring the use of machine learning to categorise online forum posts relating to self-medication by international travellers
- RFMO-02-07 - Development of a Chinese Medicine-Drug Interaction Database “PROBOT”
(SEC) Social and administrative pharmacy- RFMO-02-08 - Comparison of first line antihypertensive agents and the risk of dementia in adults with hypertension: A real-world evidence cohort study
- RFMO-02-09 - Improving access to cancer control services in low- and middle-income countries; a novel framework on policy change for pharmacists’ involvement
- RFMO-02-10 - Comparison of factors affecting turnover intentions by job fields in biopharmaceutical industry in South Korea
- RFMO-02-11 - Pharmacy Workforce Development: Leading Change in Singapore
- RFMO-02-12 - An evaluation of the Australian Community Pharmacy Agreement from a public policy perspective: Industry Policy cloaked as health policy
- RFMO-02-01 - Consumer and clinician perspectives on adverse drug events and adverse drug withdrawal effects of heart failure medications in frail older people
- RFMO-02-02 - Characteristics, content and language of deprescribing recommendations in clinical practice guidelines: A scoping review
- RFMO-02-03 - Not just being old or forgetful - measuring and quantifying causes of medication non-adherence in Norway
- RFMO-02-04 - Tech-ing up pharmacy: creating a framework to evaluate health information communication technology
- RFMO-02-05 - An exploration of drivers of COVID-19 vaccine hesitancy in Kenya
- RFMO-02-06 - Exploring the use of machine learning to categorise online forum posts relating to self-medication by international travellers
- RFMO-02-07 - Development of a Chinese Medicine-Drug Interaction Database “PROBOT”
(SEC) Social and administrative pharmacy- RFMO-02-08 - Comparison of first line antihypertensive agents and the risk of dementia in adults with hypertension: A real-world evidence cohort study
- RFMO-02-09 - Improving access to cancer control services in low- and middle-income countries; a novel framework on policy change for pharmacists’ involvement
- RFMO-02-10 - Comparison of factors affecting turnover intentions by job fields in biopharmaceutical industry in South Korea
- RFMO-02-11 - Pharmacy Workforce Development: Leading Change in Singapore
- RFMO-02-12 - An evaluation of the Australian Community Pharmacy Agreement from a public policy perspective: Industry Policy cloaked as health policy
- RFMO-02-08 - Comparison of first line antihypertensive agents and the risk of dementia in adults with hypertension: A real-world evidence cohort study
- RFMO-02-09 - Improving access to cancer control services in low- and middle-income countries; a novel framework on policy change for pharmacists’ involvement
- RFMO-02-10 - Comparison of factors affecting turnover intentions by job fields in biopharmaceutical industry in South Korea
- RFMO-02-11 - Pharmacy Workforce Development: Leading Change in Singapore
- RFMO-02-12 - An evaluation of the Australian Community Pharmacy Agreement from a public policy perspective: Industry Policy cloaked as health policy